GLP-1 for menopausal weight loss.

Perimenopause and menopause bring hormonal shifts that change how the body stores fat, uses energy, and regulates appetite. This guide explains how clinician-supervised GLP-1 therapy — including compounded semaglutide and tirzepatide — is used for weight management during this transition, who may qualify, and what evaluation looks like on kindr Health.

Why weight changes during menopause

Estrogen decline during perimenopause and menopause is associated with several metabolic changes: a shift toward visceral (abdominal) fat storage, a modest decrease in resting metabolic rate, reduced insulin sensitivity, and disrupted sleep that can affect hunger hormones. Many patients report weight gain despite no change in diet or activity level.

These metabolic changes are not a failure of willpower — they reflect underlying hormonal biology. That is one reason a growing number of clinicians consider pharmacologic options, including GLP-1 receptor agonists, when lifestyle changes alone are not enough.

How GLP-1 medications work

GLP-1 (glucagon-like peptide-1) receptor agonists mimic a hormone released naturally in the gut. They affect two systems that are particularly relevant during menopause:

• Appetite regulation. GLP-1 signaling slows gastric emptying and acts on brain regions that regulate hunger and satiety, which can reduce food intake without conscious restriction.
• Glucose metabolism. GLP-1 agonists improve insulin response after meals, which may help counter the reduction in insulin sensitivity that often accompanies menopause.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist, meaning it acts on two complementary hormonal pathways. Both are administered as a weekly subcutaneous injection when prescribed by a licensed provider.

What clinician-supervised care looks like

On kindr Health, GLP-1 therapy is only available after a licensed provider evaluates your full medical history, current medications, symptoms, and goals. The provider — not an algorithm — decides whether treatment is clinically appropriate and, if so, which medication and dose to prescribe. Menopause-specific factors that a provider will typically consider include:

• Current or recent hormone therapy (HRT) and its interaction with weight and metabolic health.
• Cardiovascular history and risk factors, which shift during and after menopause.
• Bone health and nutritional status, given that rapid weight loss can affect both.
• Sleep, mood, and other symptoms that overlap between menopause and GLP-1 side-effect profiles.

Who may qualify

Eligibility is determined solely by a licensed provider. The clinical criteria generally align with published guidance for weight management:

• BMI of 30 or greater, or
• BMI of 27 or greater with at least one weight-related condition (e.g., type 2 diabetes, hypertension, dyslipidemia).
• No contraindications to GLP-1 therapy (e.g., personal or family history of medullary thyroid carcinoma or MEN 2, active pancreatitis, current pregnancy or planning pregnancy).

Menopausal status alone does not qualify or disqualify a patient. A prescription is never guaranteed.

What to expect on kindr Health

• Intake (~10 minutes). Share health history, current medications, menopause-related symptoms, and goals.
• Provider review (within 24 hours). A licensed provider evaluates eligibility and follows up with next steps.
• Informed consent. If approved, you review and sign consent before any prescription is issued.
• Pharmacy fulfillment (within 48 hours). Compounded medication is prepared by VialsRX and shipped to your address.
• Ongoing monitoring. Follow-ups with your provider to review response, side effects, and any changes to hormone therapy or other medications.

Ready to speak with a provider?

Begin your online intake. A licensed provider will review your information — including menopause-related concerns — and follow up with next steps.

Educational content. Not medical advice. This page does not diagnose, treat, or replace evaluation by a licensed provider. Medications compounded by a licensed 503A compounding pharmacy. Not FDA-approved.